Initial experience treating lung tumors with the cyberknife

William T. Brown, Xiaodong Wu, Beatriz E. Amendola, Mark Perman, Fahed Fayad, Silvio García, Hoke T. Han, Marco Amendola, Alberto De La Zerda, James G. Schwade

Research output: Chapter in Book/Report/Conference proceeding › Chapter

2 Citations (Scopus)

Abstract

Stereotactic body radiosurgery (SBRS) of lung tumors with the CyberKnife® (Accuray Incorporated, Sunnyvale, CA) achieves excellent rates of local disease control with limited toxicity to surrounding tissues. We retrospectively reviewed treatments and outcomes for 90 patients with 109 lung lesions treated at the CyberKnife Center of Miami between March 2004 and September 2006. This monotherapy review included 49 patients with 53 primary lung cancers, 27 patients with 42 pulmonary metastases, 6 patients with external beam failure and 8 patients treated by SBRS as a boost following or before conventionally fractionated radiotherapy (3DCRT or IMRT). In the primary tumor category, 43 patients remain alive. Thirty-two have been followed 1 to 25 months (median = 11.5 months). Fortynine percent (21/43) of them have had a complete radiographic response and have been followed for a median of 18.5 months. Another 8 have evidence of at least a partial radiographic response. There have been 5 failures (5/43) within the PTV, for a local recurrence rate of 11%. Of the total 109 treated lesions, 97/109 (89%) showed radiographic evidence of at least a partial response to treatment. Six of the failures were in lesions < 20 cc; 4 were in lesions 21-100 cc and 2 were in lesions > 100 cc. All of the patients tolerated SBRS well with fatigue as the main toxicity. Two patients required hospitalization for Grade III radiation pneumonitis. We conclude that the delivery of precisely targeted, high dose, hypofractionated irradiation to lung tumors with the CyberKnife is well tolerated and has outcomes that are comparable with published results for other methods of SBRS.

Original languageEnglish
Title of host publicationTreating Tumors that Move with Respiration
PublisherSpringer Berlin Heidelberg
Pages155-163
Number of pages9
ISBN (Print)9783540698852
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Lung
Radiosurgery
Neoplasms
Radiation Pneumonitis
Fatigue
Lung Neoplasms
Hospitalization
Radiotherapy
Neoplasm Metastasis
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Brown, W. T., Wu, X., Amendola, B. E., Perman, M., Fayad, F., García, S., ... Schwade, J. G. (2007). Initial experience treating lung tumors with the cyberknife. In Treating Tumors that Move with Respiration (pp. 155-163). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-540-69886-9_17

Initial experience treating lung tumors with the cyberknife. / Brown, William T.; Wu, Xiaodong; Amendola, Beatriz E.; Perman, Mark; Fayad, Fahed; García, Silvio; Han, Hoke T.; Amendola, Marco; De La Zerda, Alberto; Schwade, James G.

Treating Tumors that Move with Respiration. Springer Berlin Heidelberg, 2007. p. 155-163.

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Brown, WT, Wu, X, Amendola, BE, Perman, M, Fayad, F, García, S, Han, HT, Amendola, M, De La Zerda, A & Schwade, JG 2007, Initial experience treating lung tumors with the cyberknife. in Treating Tumors that Move with Respiration. Springer Berlin Heidelberg, pp. 155-163. https://doi.org/10.1007/978-3-540-69886-9_17
Brown WT, Wu X, Amendola BE, Perman M, Fayad F, García S et al. Initial experience treating lung tumors with the cyberknife. In Treating Tumors that Move with Respiration. Springer Berlin Heidelberg. 2007. p. 155-163 https://doi.org/10.1007/978-3-540-69886-9_17
Brown, William T. ; Wu, Xiaodong ; Amendola, Beatriz E. ; Perman, Mark ; Fayad, Fahed ; García, Silvio ; Han, Hoke T. ; Amendola, Marco ; De La Zerda, Alberto ; Schwade, James G. / Initial experience treating lung tumors with the cyberknife. Treating Tumors that Move with Respiration. Springer Berlin Heidelberg, 2007. pp. 155-163
@inbook{3179b0b63c114cecb5e135021c89857c,
title = "Initial experience treating lung tumors with the cyberknife",
abstract = "Stereotactic body radiosurgery (SBRS) of lung tumors with the CyberKnife{\circledR} (Accuray Incorporated, Sunnyvale, CA) achieves excellent rates of local disease control with limited toxicity to surrounding tissues. We retrospectively reviewed treatments and outcomes for 90 patients with 109 lung lesions treated at the CyberKnife Center of Miami between March 2004 and September 2006. This monotherapy review included 49 patients with 53 primary lung cancers, 27 patients with 42 pulmonary metastases, 6 patients with external beam failure and 8 patients treated by SBRS as a boost following or before conventionally fractionated radiotherapy (3DCRT or IMRT). In the primary tumor category, 43 patients remain alive. Thirty-two have been followed 1 to 25 months (median = 11.5 months). Fortynine percent (21/43) of them have had a complete radiographic response and have been followed for a median of 18.5 months. Another 8 have evidence of at least a partial radiographic response. There have been 5 failures (5/43) within the PTV, for a local recurrence rate of 11{\%}. Of the total 109 treated lesions, 97/109 (89{\%}) showed radiographic evidence of at least a partial response to treatment. Six of the failures were in lesions < 20 cc; 4 were in lesions 21-100 cc and 2 were in lesions > 100 cc. All of the patients tolerated SBRS well with fatigue as the main toxicity. Two patients required hospitalization for Grade III radiation pneumonitis. We conclude that the delivery of precisely targeted, high dose, hypofractionated irradiation to lung tumors with the CyberKnife is well tolerated and has outcomes that are comparable with published results for other methods of SBRS.",
author = "Brown, {William T.} and Xiaodong Wu and Amendola, {Beatriz E.} and Mark Perman and Fahed Fayad and Silvio Garc{\'i}a and Han, {Hoke T.} and Marco Amendola and {De La Zerda}, Alberto and Schwade, {James G.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1007/978-3-540-69886-9_17",
language = "English",
isbn = "9783540698852",
pages = "155--163",
booktitle = "Treating Tumors that Move with Respiration",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Initial experience treating lung tumors with the cyberknife

AU - Brown, William T.

AU - Wu, Xiaodong

AU - Amendola, Beatriz E.

AU - Perman, Mark

AU - Fayad, Fahed

AU - García, Silvio

AU - Han, Hoke T.

AU - Amendola, Marco

AU - De La Zerda, Alberto

AU - Schwade, James G.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Stereotactic body radiosurgery (SBRS) of lung tumors with the CyberKnife® (Accuray Incorporated, Sunnyvale, CA) achieves excellent rates of local disease control with limited toxicity to surrounding tissues. We retrospectively reviewed treatments and outcomes for 90 patients with 109 lung lesions treated at the CyberKnife Center of Miami between March 2004 and September 2006. This monotherapy review included 49 patients with 53 primary lung cancers, 27 patients with 42 pulmonary metastases, 6 patients with external beam failure and 8 patients treated by SBRS as a boost following or before conventionally fractionated radiotherapy (3DCRT or IMRT). In the primary tumor category, 43 patients remain alive. Thirty-two have been followed 1 to 25 months (median = 11.5 months). Fortynine percent (21/43) of them have had a complete radiographic response and have been followed for a median of 18.5 months. Another 8 have evidence of at least a partial radiographic response. There have been 5 failures (5/43) within the PTV, for a local recurrence rate of 11%. Of the total 109 treated lesions, 97/109 (89%) showed radiographic evidence of at least a partial response to treatment. Six of the failures were in lesions < 20 cc; 4 were in lesions 21-100 cc and 2 were in lesions > 100 cc. All of the patients tolerated SBRS well with fatigue as the main toxicity. Two patients required hospitalization for Grade III radiation pneumonitis. We conclude that the delivery of precisely targeted, high dose, hypofractionated irradiation to lung tumors with the CyberKnife is well tolerated and has outcomes that are comparable with published results for other methods of SBRS.

AB - Stereotactic body radiosurgery (SBRS) of lung tumors with the CyberKnife® (Accuray Incorporated, Sunnyvale, CA) achieves excellent rates of local disease control with limited toxicity to surrounding tissues. We retrospectively reviewed treatments and outcomes for 90 patients with 109 lung lesions treated at the CyberKnife Center of Miami between March 2004 and September 2006. This monotherapy review included 49 patients with 53 primary lung cancers, 27 patients with 42 pulmonary metastases, 6 patients with external beam failure and 8 patients treated by SBRS as a boost following or before conventionally fractionated radiotherapy (3DCRT or IMRT). In the primary tumor category, 43 patients remain alive. Thirty-two have been followed 1 to 25 months (median = 11.5 months). Fortynine percent (21/43) of them have had a complete radiographic response and have been followed for a median of 18.5 months. Another 8 have evidence of at least a partial radiographic response. There have been 5 failures (5/43) within the PTV, for a local recurrence rate of 11%. Of the total 109 treated lesions, 97/109 (89%) showed radiographic evidence of at least a partial response to treatment. Six of the failures were in lesions < 20 cc; 4 were in lesions 21-100 cc and 2 were in lesions > 100 cc. All of the patients tolerated SBRS well with fatigue as the main toxicity. Two patients required hospitalization for Grade III radiation pneumonitis. We conclude that the delivery of precisely targeted, high dose, hypofractionated irradiation to lung tumors with the CyberKnife is well tolerated and has outcomes that are comparable with published results for other methods of SBRS.

UR - http://www.scopus.com/inward/record.url?scp=84891397602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891397602&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-69886-9_17

DO - 10.1007/978-3-540-69886-9_17

M3 - Chapter

SN - 9783540698852

SP - 155

EP - 163

BT - Treating Tumors that Move with Respiration

PB - Springer Berlin Heidelberg

ER -

Access to Document